Material
Two-peptide blend
Both finishes are pictured in this delivery. Packaging colour does not identify or verify the contents.
Metabolic research
CJC-1295 without DAC + Ipamorelin10 MG
CJC-1295 without DAC 5 mg + Ipamorelin 5 mg per vial. The without-DAC formulation is distinct from long-acting CJC-1295 with DAC.
Product code CI010
MaterialTwo-peptide blend
Research contextEndocrine-signaling research.
Veyvanta / profile
Compound profile
* Vial labels may use shortened names to keep the label legible. The full material and composition are stated in this profile.
Composition
CJC-1295 without DAC 5 MG + Ipamorelin 5 MG.
Research context
Endocrine-signaling research.
Identity note
CJC-1295 is declared without DAC. Evidence for the long-acting DAC analogue is not evidence for this blend or its duration of action.
Research interest
Why it draws attention
The blend combines complementary GHRH and ghrelin-receptor research pathways, attracting interest around coordinated growth-hormone secretory signaling.
Signals researchers are following
- 01
Growth-hormone and IGF-1 secretory dynamics
- 02
GHRH and ghrelin-receptor pathway interaction
Evidence levelComponent-level evidence
Published evidence / research profile
What the published research shows
A source-led view of the findings reported to date, the maturity of the evidence, and the limits that matter when interpreting it.
Evidence levelComponent-level evidence
Common research directions
- Growth-hormone and IGF-1 secretory dynamics
- GHRH and ghrelin-receptor pathway interaction
Reported findings
The component literature investigates GHRH and ghrelin-receptor signaling. Early human pharmacology characterized GH-release responses to ipamorelin. The widely cited prolonged CJC-1295 results concern a long-acting DAC-containing analogue, not the no-DAC component declared in this 5 mg + 5 mg blend.
How to read the evidence
This blend is declared as CJC-1295 without DAC plus ipamorelin. Component studies do not establish its combined performance, and results from DAC-containing CJC-1295 cannot be transferred to a no-DAC material. Sequence, molecular form, and analytical identity matter.
Selected references
This summary describes published research on the named material or its components. It does not establish safety, efficacy, equivalence, or suitability of this Veyvanta research product for human use.
Lab math
Reconstitution & measurement calculator
Convert a declared vial amount and diluent volume into nominal concentration, liquid volume, and the equivalent position on a U-100 scale.
Research product
Research productCJC-1295 without DAC + Ipamorelin / 10 MG
Component mode calculates against one declared ingredient. Total mode calculates against the full declared blend mass.
Calculated measurement
Enter a positive diluent volume and target amount to calculate.
A calculation, not a protocol
This tool performs unit conversion only. It does not recommend an amount, frequency, route, diluent, handling method, or human use. Results assume ideal mixing and a U-100 scale of 100 units per mL; validated laboratory procedures and material-specific compatibility take priority.
Product & historical codes
Current batch record
The product code identifies this material and declared strength. Supplier lot, expiry and analytical documentation are recorded separately when available.
- Batch
- CI130
- Expiry
- 1/5/28
Veyvanta internal batch record.
Find a label code
Direct product QR
This permanent link opens this exact product and strength. It does not certify an individual vial.
veyvanta.com/p/CI010Metabolic research
